ATORVASTATIN VS ROSUVASTATIN; FENOFIBRATE AS AN ADD ON: AN EXPLORATORY STUDY
Journal Title: International Journal of Pharmacy and Pharmaceutical Sciences - Year 2014, Vol 6, Issue 8
Abstract
Objective: Statins being the first choice drug for dyslipidaemia, the quest for better one among all has always been and still a question for research in the field of medicine. Objective The objective of our study was to find out the best statin among the two, Atorvastatin and Rosuvastatin, in terms of efficacy and safety; alone or in combination with Fenofibrate for the management of dyslipidaemia.Methods: This was an open label, randomized, parallel group, prospective comparative study, carried out in patients in two groups treated with Atorvastatin and Rosuvastatin (10mg each) for 6 weeks, after which Fenofibrate (67mg) was added as an add on therapy in either group for the next 4 weeks before and after treatment.Results: After the treatment, the TC, TG, LDL- C, HDL- C and Non HDL- C were comparable between two groups. The changes in the levels of TC were -15.90±5.16 (-8.53%) vs -20.70±4.83 (-11.32%) respectively in groups treated with Atorvastatin (group I) and Rosuvastatin (group II). Changes in TGs were -11.60±4.16 (-7.46%) vs -15.10±5.18 (-9.99%), respectively; change in LDL- C were -16.90±3.58 (-15.31%) vs -13.0±3.04 (-11.56%) respectively; change in HDL- C were +6.75±0.86 (+18.72%) vs +9.0±1.22 (+23.72%) respectively in each group; change in Non HDL- C were found to be -6.90±4.83 (-4.4%) vs -7.8±4.78 (-5.05%) respectively in groups I and II. After the addition of Fenofibrate (67mg) there were no significant changes in the different parameters of serum lipid profile.Conclusion: The result of our study suggests that Rosuvastatin (10mg) was more efficacious than Atorvastatin (10mg) in lipid lowering effect and HDL- C raising effect but should be used with great caution and care in patients with uncontrolled hyperglycaemia and in those with compromised hepatic status. Further addition of Fenofibrate (67mg) didn’t make any significant difference in the result.Â
Authors and Affiliations
Mohammad Arif Khan, Krishna Murti, Vaibhav Grover, Kanhaya Lal, Dharmendra Singh, Pradeep Das
Keywords
Related Articles
- EP ID EP579760
- DOI -
- Views 105
- Downloads 0
DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF SITAFLOXACIN IN BULK AND PHARMACEUTICAL DOSAGE FORMS
Objective: A simple, specific, and precise reversed phase high performance liquid chromatography method was developed and validated as per the ICH guidelines for the determination of Sitafloxacin in bulk and tablet dosag...
INFLUENCE OF A BIOLOGICALLY ACTIVE COMPOUND FROM SUBSTITUTED THIADIAZINES ON TRANSAMINASE ACTIVITY IN MYOCARDIAL HOMOGENATE IN EXPERIMENTAL MYOCARDIAL INFARCTION
Objective: Earlier works have reported on the effectiveness of the compounds of the group of substituted 5R1, 6R2, 3,4-thiadiasine-2-amines for treating experimental myocardial infarction, conditioned by the immune-modif...
DIFFERENTIAL PULSE POLAROGRAPHIC BEHAVIOR AND DETERMINATION OF ROSUVASTATIN IN PURE FORM AND IN PHARMACEUTICAL PREPARATIONS USING A STATIC MERCURY DROP ELECTRODE
Objective: Objective of study was to develop a simple, precise and accurate differential pulse polarographic analysis (DPPA) of rosuvastatin (RSV) in pure form and in pharmaceutical preparations.Methods: The DPPA was app...
TOXIC AND IMMUNOTOXIC EVALUATION OF KETAMINE AND/OR ETHANOL IN RATS DURING 28 DAYS
Objective: Studies have shown that ketamine (K) and ethanol (E) have immunomodulatory activity; however, few studies were performed with concomitant treatments. Thus, we evaluated the toxic and immunotoxic effects of thi...
RP-UFLC METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF CLOPIDOGREL, PANTOPRAZOLE AND ROSUVASTATIN IN HUMAN PLASMA: DRUG INTERACTION STUDIES
Objectives: Objective of our present study was to develop a novel ultra fast liquid chromatographic method for quantitative simultaneous estimation of Clopidogrel, Pantoprazole & Rosuvastatin in human plasma and to v...